TNFSF10 and prostate cancer: The data indicate that paclitaxel, cabazitaxel and docetaxel augment the apoptotic activity of TRAIL against both prostate cancer cell lines and sensitize these TRAIL-resistant cells to apoptotic activity of TRAIL.